You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Singapore monitors patients vaccinated against coronavirus for side effects

Singapore will continue to observe Covid-19 vaccinated patients to look out for side effects, collect this data and refine the criteria for the inoculation programme.

Coronavirus | Coronavirus Vaccine | Coronavirus Tests

Press Trust of India  |  Singapore 

coronavirus vaccine, vaccine, Covid-19 vaccine

Singapore will continue to observe COVID-19 vaccinated patients to look out for side effects, collect this data and refine the criteria for the inoculation programme following the death of an elderly man after receiving his first dose of Pfizer vaccine recently, The Straits Times reported on Saturday.

Commenting on the death, Health Minister Gan Kim Yong said on Saturday, "I want to assure Singaporeans that we will continue to monitor data not only locally, but also internationally, so that it is a continuous process that will refine our processes and criteria to ensure that it is safe."

The 72-year-old man was admitted to the intensive care unit at Tan Tock Seng Hospital and had a medical history of cancer, hypertension and hyperlipidaemia.

Gan underlined the hospital's initial assessment that there was no indication that the patient's cardiac arrest was due to the vaccination.

Everyone undergoing vaccination has to go through a thorough questionnaire to ensure that they do not have a contra-indication. A contra-indication is such as a medical condition or symptom, that is a reason for a person to not receive a particular treatment.

After the vaccination, everyone will be observed for 30 minutes. At the end of the half-hour period, those vaccinated will go through another round of questions to ensure that they are well, the minister said.

The medical team present will also give advice to patients about any adverse reaction, and where to get help.

"Whether (these incidents) are related to the (COVID) vaccination or not, we want to know if there are any such incidents so that we can investigate in-depth and better understand the situation, Gan said.

Meanwhile, Singapore continues to be on the lookout for more vaccine options even though shipments for the approved vaccines - Pfizer-BioNTech and Moderna - are coming in now.

Having more than one approved vaccine provides the country with some sort of insurance as Singapore will not need to rely on a single supplier, Education Minister and co-chair of the COVID-19 multi-ministry task force Lawrence Wong said on Friday.

A good supply of vaccines will largely determine the rate of the nation's vaccination programme, The Straits Times quoted Wong as saying.

"We are pushing out the vaccines as soon as we get the supplies, so the pace at which we can proceed with our vaccination programme really is contingent on our supply, more than anything else," he said.

But supply uncertainties remain given high global demand, Wong cautioned.

Supply bottlenecks could also be caused by a stoppage in the manufacturing plant, or an export restriction, or some other logistical issues, he noted.

"But we are happy now that we not only have Pfizer, we also have Moderna, so we have some diversification benefits. The supplies have come in February, and we are expecting another supply coming through every month," Wong said.

Apart from Pfizer and Moderna vaccines, Singapore has also made advanced purchase agreements with China's Sinovac vaccine.

However, Sinovac is yet to be approved as more data is still pending for the Health Sciences Authority to ensure it is safe, Wong said.

"Beyond Sinovac, we continue to look at other options, and so that search for other vaccine options continues. We are not stopping at just three vaccines," he said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, February 20 2021. 08:59 IST